Pfizer Pflat In 2005: Revenue Will Be "Substantially Unchanged"
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer expects flat revenue growth during 2005 in the face of patent expirations and the poor performance of its COX-2 inhibitors
You may also be interested in...
No Merger Needed: Pfizer Efficiency Program To Generate $4 Bil. In Savings
Pfizer is launching a productivity initiative to generate $4 bil. in annual cost savings by 2008, the company announced during its New York City analyst meeting April 5
Celebrex, Bextra Stabilizing After FDA Advisory Committee Review, Pfizer Says
Company is predicting a return to growth in the COX-2 category once FDA completes work on new labeling. Celebrex and Bextra "will remain critical treatment options for many years to come," Pfizer tells analysts.
No Merger Needed: Pfizer Efficiency Program To Generate $4 Bil. In Savings
Pfizer is launching a productivity initiative to generate $4 bil. in annual cost savings by 2008, the company announced during its New York City analyst meeting April 5